Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 18 studies | 28% ± 12% | |
plasmacytoid dendritic cell | 16 studies | 25% ± 9% | |
naive B cell | 12 studies | 20% ± 4% | |
dendritic cell | 9 studies | 28% ± 15% | |
endothelial cell of lymphatic vessel | 7 studies | 36% ± 19% | |
oligodendrocyte | 6 studies | 26% ± 9% | |
memory B cell | 5 studies | 20% ± 5% | |
endothelial cell | 5 studies | 25% ± 7% | |
CD4-positive, alpha-beta T cell | 5 studies | 28% ± 8% | |
fibroblast | 5 studies | 21% ± 3% | |
retinal cone cell | 5 studies | 37% ± 10% | |
smooth muscle cell | 5 studies | 27% ± 13% | |
plasma cell | 4 studies | 33% ± 12% | |
retinal rod cell | 4 studies | 32% ± 4% | |
glutamatergic neuron | 4 studies | 40% ± 14% | |
extravillous trophoblast | 3 studies | 27% ± 9% | |
myofibroblast cell | 3 studies | 29% ± 5% | |
immature B cell | 3 studies | 19% ± 2% | |
cardiac muscle cell | 3 studies | 17% ± 1% | |
GABAergic neuron | 3 studies | 39% ± 3% | |
T cell | 3 studies | 23% ± 3% | |
lymphocyte | 3 studies | 29% ± 7% | |
neuron | 3 studies | 22% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 100% | 4860.93 | 962 / 966 | 97% | 18.48 | 510 / 527 |
lung | 100% | 3553.04 | 577 / 578 | 95% | 15.66 | 1093 / 1155 |
esophagus | 97% | 3235.42 | 1402 / 1445 | 92% | 16.14 | 169 / 183 |
stomach | 91% | 2225.74 | 327 / 359 | 97% | 19.58 | 278 / 286 |
uterus | 97% | 1790.59 | 165 / 170 | 87% | 15.73 | 400 / 459 |
bladder | 100% | 4946.52 | 21 / 21 | 79% | 17.53 | 396 / 504 |
breast | 67% | 696.23 | 308 / 459 | 90% | 11.84 | 1006 / 1118 |
prostate | 96% | 2096.97 | 234 / 245 | 49% | 2.81 | 246 / 502 |
ovary | 78% | 878.31 | 140 / 180 | 61% | 4.62 | 261 / 430 |
thymus | 90% | 1216.17 | 586 / 653 | 45% | 3.77 | 272 / 605 |
liver | 79% | 1174.62 | 179 / 226 | 55% | 3.95 | 222 / 406 |
skin | 41% | 545.83 | 736 / 1809 | 82% | 21.10 | 388 / 472 |
brain | 53% | 690.80 | 1388 / 2642 | 69% | 7.95 | 487 / 705 |
adrenal gland | 82% | 820.99 | 211 / 258 | 28% | 2.43 | 65 / 230 |
lymph node | 0% | 0 | 0 / 0 | 100% | 63.94 | 29 / 29 |
spleen | 100% | 5903.73 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 2214.75 | 1325 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 5705.74 | 894 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 24.34 | 43 / 45 |
pancreas | 2% | 15.22 | 5 / 328 | 94% | 22.07 | 167 / 178 |
heart | 92% | 3394.08 | 796 / 861 | 0% | 0 | 0 / 0 |
kidney | 30% | 338.47 | 27 / 89 | 57% | 5.21 | 517 / 901 |
adipose | 86% | 1190.16 | 1036 / 1204 | 0% | 0 | 0 / 0 |
muscle | 32% | 306.77 | 253 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 10% | 0.69 | 8 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0016485 | Biological process | protein processing |
GO_0006509 | Biological process | membrane protein ectodomain proteolysis |
GO_0042987 | Biological process | amyloid precursor protein catabolic process |
GO_0001890 | Biological process | placenta development |
GO_2000049 | Biological process | positive regulation of cell-cell adhesion mediated by cadherin |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005886 | Cellular component | plasma membrane |
GO_0005634 | Cellular component | nucleus |
GO_0004222 | Molecular function | metalloendopeptidase activity |
GO_1902945 | Molecular function | metalloendopeptidase activity involved in amyloid precursor protein catabolic process |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0017124 | Molecular function | SH3 domain binding |
Gene name | ADAM19 |
Protein name | Disintegrin and metalloproteinase domain-containing protein 19 (ADAM 19) (EC 3.4.24.-) (Meltrin-beta) (Metalloprotease and disintegrin dendritic antigen marker) (MADDAM) ADAM metallopeptidase domain 19 ADAM19 protein |
Synonyms | MLTNB FKSG34 |
Description | FUNCTION: Participates in the proteolytic processing of beta-type neuregulin isoforms which are involved in neurogenesis and synaptogenesis, suggesting a regulatory role in glial cell. Also cleaves alpha-2 macroglobulin. May be involved in osteoblast differentiation and/or osteoblast activity in bone (By similarity). . |
Accessions | H0YC66 ENST00000517374.5 ENST00000257527.9 [Q9H013-2] Q9H013 ENST00000517951.5 Q8TBU7 ENST00000517905.1 [Q9H013-1] E5RIS2 |